- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04283890
PHP and Immunotherapy in Metastasized UM (CHOPIN)
Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Uveal melanoma (UM) is an uncommon malignancy (0.6-0.7 cases/100.000/year) that, in the case of metastatic stage, has a poor prognosis for response to treatment and survival. It is remarkable for its purely hematogenous pattern of dissemination, most commonly to the liver (60%) and lungs (25%). Current approaches using percutaneous hepatic perfusion (PHP) with melphalan resulted in response rates of up to 40% in the liver (1, 2) (for results of our own phase II study see paragraph 6.3.2). However, a main part of the patients developed extrahepatic disease in the follow-up, whereas the liver metastases were mainly stable.
Checkpoint inhibitors have been shown to improve overall survival in metastasized cutaneous melanoma in phase III studies (3-6), but seem to have limited activity as monotherapies in metastasized uveal melanoma (7-9). The combination of ipilimumab and nivolumab has achieved 2 out of 6 patients PR in a retrospective analysis (10). Interestingly, both patients had a liver-directed therapy (SIRT and chemoembolization) before the immunotherapy.
Combination of radio-frequency ablation (RFA) and anti-CTLA-4 enhanced antigen-loading of dendritic cells, and induced long-lasting anti-tumor immune responses in a murine melanoma model without induction of any severe side effects (11, 12). A phase Ib/II trial by Blank et al. (13) showed unconfirmed responses in some patients when RFA was combined with ipilimumab in uveal melanoma, but long-term disease stabilization was not achieved. Most of the responses were seen in extrahepatic metastases. Combining percutaneous hepatic perfusion (PHP) with checkpoint inhibitors could together lead to control of hepatic and extrahepatic disease. Therefore, we propose the current trial: Phase1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma (CHOPIN).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Ellen W. Kapiteijn, MD, PhD
- Phone Number: +31-71-5263486
- Email: h.w.kapiteijn@lumc.nl
Study Contact Backup
- Name: Mark C. Burgmans, MD, PhD
- Phone Number: +31-71-5262052
- Email: m.c.burgmans@lumc.nl
Study Locations
-
-
Zuid-Holland
-
Leiden, Zuid-Holland, Netherlands, 2333 ZA
- Recruiting
- Leiden University Medical Center
-
Contact:
- Ellen Kapiteijn, MD, PhD
- Phone Number: +31-71-5263486
- Email: h.w.kapiteijn@lumc.nl
-
Contact:
- Frank Speetjens, MD, PhD
- Phone Number: +31-71-5263486
- Email: f.m.speetjes@lumc.nl
-
Principal Investigator:
- Ellen Kapiteijn, MD, PhD
-
Sub-Investigator:
- Frank Speetjens, MD, PhD
-
Sub-Investigator:
- Thaïs Tong, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18-75 yrs
- World Health Organization (WHO) Performance Status 0 or I
- 50% or less histologically or cytologically confirmed unresectable metastatic uveal melanoma in the parenchyma of the liver
- Hepatic metastases, confined to or predominantly in the liver
- No prior systemic treatment (including chemotherapy, vaccine therapy, monoclonal Ab treatment, IL-2)
- Local pre-treatment of uveal melanoma metastases is allowed (resection and/or thermal ablation), except for chemotherapy containing procedures (e.g. chemoembolization) and radio-embolization, and as long as patients have progressed with measurable disease according to RECIST 1.1
- No concurrent systemic immunosuppressive medications ≥ 10mg/day prednisone or equivalent. Topical, inhaled, nasal and ophthalmic steroids, and adrenal replacement therapy are allowed.
- Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥ 1.0x109/L, Platelets ≥ 100 x109/L, Hemoglobin ≥ 6.5 mmol/L, Creatinine ≤ 2x ULN, AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, Total bilirubin ≤ 1.5 X ULN, INR and PTT in normal range, LDH < 2xULN
- Women of child bearing potential (WOCBP) must agree to use a reliable form of contraceptive as described in paragraph 5.4.
- Men must agree to the use of male contraception as described in paragraph 5.4.
- Absence of additional severe and/or uncontrolled concurrent disease
- No prior, or ongoing other malignancy, except adequately treated basal cell or squamous cell skin cancer, cervical cancer in situ or adequately treated other cancer with eradicative intent for which the patient has been continuously disease-free for > 2 years.
- No aberrant vascular anatomy of the liver that precludes PHP
Exclusion Criteria:
- Cerebral or meningeal metastasized uveal melanoma
- Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy;
- Prior immunotherapy (tumor vaccine, cytokine, or growth factor)
- Known history of infection with Human Immunodeficiency Virus;
- Active infection requiring therapy, positive serology for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA)
- History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), significant arrhythmias and severe valvular disease must be evaluated for risks of undergoing general anesthesia.
- History or evidence of clinically significant pulmonary disease e.g. severe COPD that precludes the use of general anesthesia.
- Underlying medical conditions that, in the Investigator's opinion, will make the administration of study treatment hazardous or obscure the interpretation of toxicity determination or adverse events;
- Latex allergy, and known hypersensitivity/allergy to ipilimumab, nivolumab, melphalan or heparin
- Prior Whipple's Surgery
- Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
- History of or current immunodeficiency disease, splenectomy or splenic irradiation; prior allogeneic stem cell transplantation;
- Patients who are unable to be temporarily removed from chronic anti-coagulation therapy.
- Patients with active bacterial infections with systemic manifestations (malaise, fever, leucocytosis) are not eligible until completion of appropriate therapy.
- Use of other investigational drugs before study drug administration for systemic malignancy
- Pregnancy or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase Ib
|
The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma.
In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma.
In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
|
Active Comparator: Phase II - Combination treatment
|
The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma.
In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma.
In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
|
Active Comparator: Phase II - PHP
|
The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma.
In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity and safety of treatment
Time Frame: 36 weeks
|
Dose limiting toxicities, maximum tolerated dose and recommended phase dose of the combination ipilimumab/nivolumab and PHP in patients with unresectable, histologically confirmed hepatic metastasis of uveal melanoma in phase Ib part.
|
36 weeks
|
Efficacy and safety
Time Frame: 1 year
|
Description of PFS according to RECIST 1.1 at one year in the PHP group versus PHP + ipilimumab/nivolumab group in the phase II part.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: 1 year
|
Description of response rate and overall survival, overall clinical response, and duration of response
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ellen W. Kapiteijn, MD, PhD, Leiden University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Eye Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Uveal Diseases
- Neuroendocrine Tumors
- Nevi and Melanomas
- Eye Neoplasms
- Melanoma
- Uveal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Melphalan
- Ipilimumab
Other Study ID Numbers
- NL69508.058.19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveal Melanoma, Metastatic
-
GlaxoSmithKlineWithdrawnCancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
Alliance for Clinical Trials in OncologyWithdrawnMetastatic Uveal Melanoma | Advanced Uveal Melanoma | Unresectable Uveal Melanoma
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the LiverUnited States
-
Memorial Sloan Kettering Cancer CenterIovance Biotherapeutics, Inc.RecruitingMelanoma | Metastatic Melanoma | Metastatic Uveal Melanoma | Uveal MelanomaUnited States
-
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer Center; Institut Curie Paris; Moffitt Cancer...Active, not recruitingMetastatic Uveal Melanoma | Stage IV Uveal Melanoma AJCC v7United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbActive, not recruitingMetastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver | Stage IV Uveal Melanoma AJCC v7United States
-
Jose Lutzky, MDBristol-Myers Squibb; United States Department of DefenseActive, not recruitingMetastatic Uveal MelanomaUnited States
-
Thomas Jefferson UniversityVerastem, Inc.Active, not recruitingMetastatic Uveal MelanomaUnited States
Clinical Trials on Ipilimumab and nivolumab
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
Ontario Clinical Oncology Group (OCOG)Bristol-Myers SquibbActive, not recruitingMetastatic Renal Cell CarcinomaCanada, Australia
-
Bristol-Myers SquibbCompletedCarcinoma, Renal CellUnited States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers SquibbUnknown
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers Squibb; Astex Pharmaceuticals, Inc.Not yet recruitingMelanoma | Non Small Cell Lung CancerItaly
-
Universitätsklinikum KölnZKS KölnWithdrawnCervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb; Cancer Research Institute, New York CityCompletedAdvanced Metastatic Cancer | Advanced Prostate CancerUnited States